Schott Pharma jumps after FY results and 2025 outlook
** Shares in Schott Pharma 1SXP.DE jump around 6% in early Frankfurt trade after the German pharmaceutical packaging company posted higher FY results and gave an upbeat outlook for 2025
** The company posts FY revenue at 957 million euros, up 7% y/y; EBITDA comes in at 258 million euros vs 239 million
** For 2025, it expects significant revenue growth at constant currencies in the high single digits and an increase in EBITDA, with EBITDA margin at the 2024 level
** The stock, which has lost 17.8% YTD, tops Germany's mid-cap index .MDAXI
Reporting by Ozan Ergenay
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
